title: Secretory phospholipase A2 induces phospholipase Cgamma-1 activation and Ca2+ mobilization in the human astrocytoma cell line 1321N1 by a mechanism independent of its catalytic activity.
abstract: The effect of secretory phospholipase A2 (sPLA2) on intracellular Ca2+ signaling in human astrocytoma cells was studied. sPLA2 increased cytosolic [Ca2+] ([Ca2+]c) in both Ca2+-containing and Ca2+-free medium, thus suggesting Ca2+ release from intracellular stores. The activation by sPLA2 of arachidonate release via cytosolic PLA2 (cPLA2) was also independent of extracellular Ca2+. As sPLA2 requires Ca2+ for activity, these results indicate that both Ca2+ mobilization and cPLA2 activation induced by sPLA2 are unrelated to phospholipase activity but dependent on signaling mechanisms. The sPLA2-induced [Ca2+]c peak was sensitive to Bordetella pertussis toxin and inhibited by caffeine, suggesting its mediation by inositol 1,4,5-trisphosphate (IP3). sPLA2 induced tyrosine phosphorylation and membrane targeting of phospholipase Cgamma-1 (PLCgamma-1). Moreover, the Ca2+ peak was sensitive to protein tyrosine kinase inhibitors. sPLA2 activates two signaling pathways: one leading to the activation of the MAP kinase/cPLA2 cascade and another leading to PLCgamma activation and Ca2+ release.
authors.affiliation: Instituto de Biología y Genética Molecular, Facultad de Medicina, Consejo Superior de Investigaciones Científicas and Universidad de Valladolid, Valladolid, 47005-, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Hernández
authors.forename: M J
authors.initials: MJ
authors.lastname: Barrero
authors.forename: J
authors.initials: J
authors.lastname: Alvarez
authors.forename: M
authors.initials: M
authors.lastname: Montero
authors.forename: M
authors.initials: M
authors.lastname: Sánchez Crespo
authors.forename: M L
authors.initials: ML
authors.lastname: Nieto
mesh_terms: D001254:Astrocytoma / Q000378:metabolism*; D016227:Benzoquinones; D002110:Caffeine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000378:metabolism; D002384:Catalysis; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism*; D047029:Lactams, Macrocyclic; D008954:Models, Biological; D037342:Pertussis Toxin; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D051966:Phospholipase C gamma; D010741:Phospholipases A / Q000378:metabolism*; D054467:Phospholipases A2; D010766:Phosphorylation; D011809:Quinones / Q000494:pharmacology; D017828:Rifabutin / Q000031:analogs & derivatives; D015398:Signal Transduction; D013997:Time Factors; D014407:Tumor Cells, Cultured; D010738:Type C Phospholipases / Q000378:metabolism*; D014443:Tyrosine / Q000378:metabolism; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
chemical_list: D016227:Benzoquinones; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D047029:Lactams, Macrocyclic; D010726:Phosphodiesterase Inhibitors; D011809:Quinones; D010566:Virulence Factors, Bordetella; D017828:Rifabutin; D002110:Caffeine; D014443:Tyrosine; C020754:herbimycin; D037342:Pertussis Toxin; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D010741:Phospholipases A; D054467:Phospholipases A2; D010738:Type C Phospholipases; D051966:Phospholipase C gamma; D002118:Calcium